Biotech | March 14, 2022
Zolgensma used pre-symptomatically enables kids to stand and walk
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
